Results 211 to 220 of about 67,507 (290)

Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Companion diagnostics use biomarker‐based assays to stratify patients for precision therapies, improving outcomes while reducing ineffective treatment and side effects. This review summarizes the evolution, regulatory landscape, clinical applications, and technological platforms of CDx, highlighting their role in biomarker‐driven precision therapy.
Yuesong Wu, Rou Xue, Xiangwen Luo, Jiangnan Liao, Zongbo Zhang, Jinhai Deng, Teng Liu, Xin Li, Zhe‐Sheng Chen, Mingzhu Yin   +9 more
wiley   +1 more source

Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.

JAMA Netw Open
Barata PC, Corrigan JK, La J, Culnan JM, Akama-Garren E, Dulberger KN, Dumontier C, Hansen J, Bihn JR, Bitting RL, Brophy MT, Cheng HH, Cooperberg MR, Do NV, Dorff T, Fojo AT, Gaziano JM, Goryachev SD, Halabi S, Hauger RL, Nanus DM, Rebbeck TR, Pan CX, Schoen MW, Swinnerton KN, Myrie K, Ramoni RB, Fillmore NR, Paller CJ, Rettig MB.   +29 more
europepmc   +1 more source

Real-World Treatment Patterns Before and After Metastatic Castration-Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital-Based, Multicenter Database. [PDF]

Prostate Cancer
Shiota M, Xu L, Oguri T, Tanaka M.
europepmc   +1 more source

Clinical Application of Peripheral Blood Biomarkers for Solid Tumors

MedComm, Volume 7, Issue 3, March 2026.
Peripheral blood biomarkers provide a minimally invasive, dynamic, and potentially more accurate means to obtain a comprehensive tumor profile. Technologies for detecting them are advancing, and with the help of artificial intelligence, they are being used more and more often for cancer diagnosis, prognostic assessment, and therapeutic monitoring ...
Xinru Tu, Mengyan Tu, Junfen Xu
wiley   +1 more source

Clinical outcomes of lutetium-177-PSMA-617 in a racially diverse cohort of patients with metastatic castration-resistant prostate cancer. [PDF]

Oncologist
Gerke MB, Bedmutha A, Marra A, Liu Y, Brown JT, Nazha B, Berchuck JE, Parikh RB, Ahmed S, Ciuro JA, Hartman C, McClintock GR, Caulfield S, Kucuk O, Carthon BC, Schuster DM, Muzahir S, Bilen MA.   +17 more
europepmc   +1 more source

Castration-Resistant Metastatic Prostate Carcinoma [PDF]

, 2019
gil falcao, João Vasco Barreira
openaire   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based Studies. [PDF]

Cancer Med
Stock SR, Parrish JA, Burns MT, Janes JL, Waller J, De Hoedt AM, Ghate S, Kim J, Shui IM, Freedland SJ.   +9 more
europepmc   +1 more source